

# Exposure assessment and the Chemical Safety Report

Société Française de Toxicologie  
28 Septembre 2012

Hélène Magaud  
Registration Directorate  
Computational Assessment Unit  
ECHA



# Overview

- Recap on REACH requirements
- Assessment workflow
- Scope of exposure assessment
- Few ECHA's observations related to the exposure scenarios received so far

# Recap on REACH requirements

## CSA in a nutshell


- Determine the hazards based on the information required for registration of the substance
- Describe the conditions of safe use (operational conditions and risk management)
  - => set of **exposure scenarios** addressing all identified uses
  - Estimate the expected exposure under these conditions
  - Compare the expected exposure with the hazards
  - Conclude whether control of risk is demonstrated; refine the assessment, if needed;
- *Annex I of REACH sets out the general provisions for the assessment*

## When is a CSA required?


- Required if the substance is manufactured or imported at 10 tonnes or more per year.
- The CSA includes exposure assessment and risk characterisation for all the identified hazards
  - if one of the criteria is met to classify the substance as hazardous, or
  - if the substance is to be treated as PBT/vPvB, or
  - if information requirements are adapted based on exposure considerations according to Annex XI (3)
- Identified hazards = adverse effects observed based on guideline studies (or other adequate information)

# Assessment work flow

# Assessment Workflow



# Risk Characterization (RC)





# Assessment types

Assessment Type	Exposure Scenario (conditions of use)	Exposure estimation	Risk characterization
Quantitative	yes	yes	$RCR < 1$
Semi-quantitative	yes	yes	exposure < threshold + additional argument
Qualitative	yes	may be required to demonstrate control of risks	control strategy corresponds to hazard

# Mandatory elements of the CSA/CSR (1)

Assessment of intrinsic properties/hazards:

- Physicochemical properties, “environmental fate” properties
- Human health hazards
  - Local effects (skin, eyes, or respiratory tract)
  - Systemic effects (intake via skin, inhalation or oral)
  - effects after single event exposure (short term) or after repeated/long-term exposure
  - effects due to flammability, explosivity, oxidising potential.
- Environmental hazards:
  - Adverse effects on organisms in water, sediments, soil or waste water treatment plant; adverse effects in the food-chain (aquatic and terrestrial)

## Mandatory elements of the CSA/CSR (2)

- Use identification for the full life cycle
- Exposure assessment
  - Conditions of use (operational condition and risk management)
  - Corresponding release and exposure estimates
- Risk characterisation
  - Quantitative: Compare estimated exposure with PNEC or DNEL.  $RCR < 1$  indicates control of risk
  - Qualitative: Compare estimated exposure and/or foreseen risk management with type and level of hazard.

# **Scope of exposure assessment**

**From study records  
to hazard assessment  
conclusions in IUCLID 5.4**

## Toxicological hazard conclusions

- The endpoint summary for section 7 of IUCLID 5.4 has been expended to better support
  - Transparency in the hazard conclusion (e.g. derivation of DNELs)
  - Identification of the scope of exposure assessment

## Hazard assessment information in IUCLID

The screenshot displays the IUCLID software interface for hazard assessment. On the left, a tree view shows the hierarchy of toxicological information, with '7.3 Irritation / corrosion' and its sub-item 'Irritation / corrosion' highlighted. The main panel is titled 'Key value for chemical safety assessment' and contains three input fields for 'Skin irritation / corrosion', 'Eye irritation', and 'Respiratory irritation'. A red arrow points to the dropdown menu for 'Skin irritation / corrosion', which is open, showing a list of hazard levels: 'not irritating', 'irritating', 'slightly irritating', 'moderately irritating', 'highly irritating', 'corrosive', and 'highly corrosive'. Below the input fields is a 'Discussion' section with a toolbar containing icons for file operations and text formatting. The bottom of the interface shows a status bar with 'Normal' text style, 'Agency FB' font, and size '8'.

# Example (1): Overview on endpoint summaries in section 5.11 of the CSR

**Source:** IUCLID 5.4, section 7

Endpoint	Route	Dose descriptor or qualitative effect characterisation; test type;
Acute toxicity	Oral	No adverse effect observed
Acute toxicity	Dermal	No adverse effect observed
Acute toxicity	inhalation	No adverse effect observed
Irritation / Corrosivity	Skin	irritating
Irritation / Corrosivity	Eye	irritating
Irritation / Corrosivity	respiratory	No study available
Sensitisation	Skin	No adverse effect observed (not sensitising)
Repeated dose toxicity	Oral	NOAEL: 700 mg/kg bw/day (subacute; rat)
Repeated dose toxicity	Dermal	No study available
Repeated dose toxicity:	inhalation	No study available
Mutagenicity		No adverse effect observed (negative)
Reproductive toxicity: fertility impairment	Oral	No adverse effect observed

## Example (2): Hazard conclusions in section 5.11 of the CSR

**Source:** IUCLID 5.4, section 7 (overall toxicological summary)

Route	Type of effect	Hazard conclusion	Most sensitive endpoint (referring to original study)
Inhalation	Systemic effect - Long-term	DNEL = 24.7 mg/m <sup>3</sup>	Repeated dose toxicity (oral)
	Systemic effects -Acute	No hazard identified	Acute toxicity (Inhalation)
	Local effects - Long-term	Hazard unknown (no further information necessary)	
	Local effects - Acute	Hazard unknown (no further information necessary)	
Dermal	Systemic effect - Long-term	DNEL = 7 mg/kg bw /day	Repeated dose toxicity (oral)
	Systemic effects -Acute	No hazard identified	Acute toxicity (dermal)
	Local effects - Long-term	Low hazard	Skin irritation/corrosion
	Local effects - Acute	Low hazard	Skin irritation/corrosion
Eyes	Local effects - Acute	Low hazard	Eye irritation

Remark: Table expected for workers and for general population



## Example (3): Scope of exposure assessment for human health in section 9.02

Route	Type of effect	Type of risk characterisation	Hazard conclusion (see section 5.11)
<b>Inhalation</b>	Systemic effect - Long-term	Quantitative	DNEL = 24.7 mg/m <sup>3</sup>
	Systemic effects -Acute	Not required	No hazard identified
	Local effects - Long-term	Qualitative	Hazard unknown (no further information required)
	Local effects - Acute	Qualitative	Hazard unknown (no further information required))
<b>Dermal</b>	Systemic effect - Long-term	Quantitative	DNEL = 7 mg/kg bw /day
	Systemic effects -Acute -	Not required	No hazard identified
	Local effects - Long-term	Qualitative	Low hazard
	Local effects - Acute	Qualitative	Low hazard
<b>Eyes</b>	Local effects –Acute	Qualitative	Low hazard

## Example (4): Explanation of DNEL derivation in section 5.11 of the CSR

		Assessment factors for DNEL derivation
Inhalation (Long-term - systemic effects)	<b>DNEL derivation method:</b> ECHA REACH guidance  <b>Dose descriptor starting point</b> NOAEC = 617 mg/m <sup>3</sup>	AF for difference in duration of exposure: 2 ( <i>DNEL is based on an oral 90 day study</i> ) AF for interspecie differences: 1 ( <i>AF not used for inhalation route</i> ) AF for other interspecie differences: 2.5 AF for intra species differences: 5 (workers)  Overall Assessment Factor: 25
Dermal (Long-term - systemic effects)	<b>DNEL derivation method:</b> ECHA REACH guidance  <b>Dose descriptor starting point</b> NOAEL = 700 mg/kg bw/day	AF for difference in duration of exposure: 2 ( <i>based on an oral 90 day study</i> ) AF for interspecie differences: 4 ( <i>experimental animal was rat</i> ) AF for other interspecie differences: 2.5 AF for intra species differences: 5 ( <i>this is for workers</i> ) AF for remaining uncertainties:  Overall Assessment Factor: 100

*Explanation for route to route extrapolation: .....*

# **Few observations on CSRs from first registration wave**

## What has been submitted to ECHA

- For about 1400 substances CSRs with exposure scenarios are principally available. That is a success.
- The CSR information is submitted in form of text documents attached to the Technical Dossier.
- The Technical Dossier is submitted in electronic format and usually contains
  - the brief description of identified uses in section 3.5 (required to be consistent with the titles of the exposure scenarios)
  - no information related to guidance on safe use
  - no information related to expected exposure or risk
- ECHA does not see the ES for communication.

## Observations on the use description (1)

- Very generic, does not support understanding of what is practically done with the substance; no descriptive narratives (often just a bare list of descriptors)
- Includes often nearly all use descriptors (regardless of whether this is plausible or relevant for the substance)
  - Registrants try to cover everything i) just to be on the safe side or ii) to include everything they have received from downstream
  - Registrants have copied their use descriptions from lead registrant or even from a generic CSR generated at sector level

## Observations on use description (2)

- The use descriptions lack consistency, e.g.
  - Article service life reported although the substance is described as a processing aid
  - Use descriptors indicating wide dispersive use are reported for industrial sites

## Observations on scope of exposure assessment

- Environmental part of the ES missing
- Exposure men via environment missing
- RMM corresponding to qualitative hazards not addressed
- RMM related to physicochemical hazards not addressed

## Support provided by ECHA

- All existing guidance and practical guide
- Chesar (Chemical Safety Assessment and Reporting tool): IT tool developed by ECHA to support registrants in carrying out their CSA and preparing their CSR

<http://chesar.echa.europa.eu/>

- NEW: Practical guide 14: How to prepare toxicological summaries in IUCLID and how to derive DNELs
- NEW (to be published with IUCLID 5.4.1 in October): IUCLID Helptext for section 3.5 (life cycle description) and for endpoint summaries



**Merci.**

Hélène Magaud  
[helene.magaud@echa.europa.eu](mailto:helene.magaud@echa.europa.eu)